We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.14 | 2.10 | 2.18 | 2.20 | 2.19 | 2.19 | 604,698 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/1/2018 17:59 | I guess all you guys who have owned their shares for 5 or 10 years must be looking at upstarts like myself and be giving a deep sigh. Apologies for the over exuberance and regularity of the postings. | hamhamham1 | |
21/1/2018 17:09 | In the proactive interview he was talking about a possible multi billion dollar revenue drug so what share price could that imply assuming he is right ? | jp1962 | |
21/1/2018 17:01 | Naturally as we get closer to the results, the share price is likely to rise further but probably settle around 250-273p pre results.GLA | ny boy | |
21/1/2018 14:59 | I think we will break the 200p barrier early this week, then it may drop down below for a bit as sells are triggered. Bit then push back through 200p again. Onwards and upwards. Let's just see what happens. Enjoy. GLA. | hamhamham1 | |
21/1/2018 14:51 | Having read and reread all the available data I take the view that a doubling of the share price over the next 2-3 months is very possible, ending up with around a tripling by the end of the year to perhaps £6 or thereabouts. More than that seems very optimistic to me. In the fullness of time, say 3-4 years, it could move higher if market take up is sufficiently good. I think it will take quite a few years for a 10 fold increase, let alone some of the wilder estimates I’ve seen here. $20K per patient per year is a great deal of money in many parts of the world. A bid for the company, or significant progress on the treatment of another medical condition, could raise the stakes of course. I’m not banking on that, though, and will be very satisfied if it does as well as I think it might. The key thing is not to get out prematurely and miss out. | aimingupward2 | |
21/1/2018 14:40 | 3 interviews on Friday that I am aware of - see my post 10411. Of these 3, only in the vox markets interview (perhaps as a result of the less formal style of interviewing ) does Tim McCarthy reveal that a LOT of patients and investigators have asked if it would be possible for the patients to continue using Lupuzor. interview starts at 27:01 32:14 – had a lot of requests from patients and investigators to ask if it is possible for the patients to continue using the drug – In the other two interviews, Tim McCarthy simply says that patients and investigators have asked if it would be possible for the patients to continue to use Lupuzor. He has not given any indication of how many patients and investigators have asked. Although, reading between the lines, it does sound as if it is a good number. In the vox interview he reveals that it is lots... | metis20 | |
21/1/2018 12:56 | cant see what he has written would damage your reputation?? | brad44 | |
21/1/2018 12:20 | Tim McCarthy (IMM Chairman) Two Interviews, 18/1/2018: "I am really excited that in a relatively short period of time, we could have a drug [Lupuzor] on the market which would benefit literally millions of patients across the world for a condition for which they havn't had an effective treatment ever... ...to be a relatively small UK company, sitting here as we do with this late stage product, owning 100% of it, from a commercial perspective that's really exciting as well because this is potentially a multi-billion dollar drug...this is definately going to be a product which will sell in the multi-billion dollars per year... ...we [IMM] are still only valued at £200 - £250 million. In pharmaceutical terms and the prospect of this drug, that is absolutely still very tiny when you consider the potential of this drug...There are a number of discussions going on...so its exciting on a number of fronts." 6 min 45 sec: "This [Lupuzor] could be selling in the billions of dollars per year, every year...We are ticking all the boxes in terms of the market potential, the profile of drug [Lupuzor] the lack of competition, we as a company own it 100%, so going on from here, the benefit to our shareholders in terms of the uplift in value of IMM based on this drug is exponential potentially..." 27 min 2 sec: | hottingup | |
21/1/2018 12:12 | Barbie Manchester Woman named Barbie Manchester from North Carolina with terminal Lupus took Lupuzor under Right to Try legislation, with the result she didn't know she was ill during that time. Since then she has had other treatments none of which gave the benefits of lupuzor: The drug administered in her first trial, Lupuzor, worked well. But after three years, the trial ended. “That was very devastating,” she said. “For me personally, that was the best medication. You’d never have known I was sick.” Melanie Regnaud Woman named Melanie Regnaud who is a longstanding lupus sufferer takes Lupuzor and gets better. Now leading a normal life and has her first ever boyfriend: May 2017 article - Translation: Melanie started a new job at the beginning of the year, she has a boyfriend and a family who adores her. Since she started a new treatment, Lupuzor, she is doing better. She only takes 5 mg of corticosteroids and always goes on medical appointments every three months. She dreams of having her own house and her own car. She is thinking of starting a family; she does not know if it will be possible but she hopes. "If you told me, six or seven years ago, that in 2017, I would meet a man who loves me, that I was going to work, that I would be alive and that I would be better, I would not have believed you!" | englishlongbow | |
21/1/2018 11:47 | Barbie Manchester Woman named Barbie Manchester from North Carolina with terminal Lupus took Lupuzor under Right to Try legislation, with the result she didn't know she was ill during that time. Since then she has had other treatments none of which gave the benefits of lupuzor: The drug administered in her first trial, Lupuzor, worked well. But after three years, the trial ended. “That was very devastating,” she said. “For me personally, that was the best medication. You’d never have known I was sick.” Melanie Regnaud Woman named Melanie Regnaud who is a longstanding lupus sufferer takes Lupuzor and gets better. Now leading a normal life and has her first ever boyfriend: May 2017 article - Translation: Melanie started a new job at the beginning of the year, she has a boyfriend and a family who adores her. Since she started a new treatment, Lupuzor, she is doing better. She only takes 5 mg of corticosteroids and always goes on medical appointments every three months. She dreams of having her own house and her own car. She is thinking of starting a family; she does not know if it will be possible but she hopes. "If you told me, six or seven years ago, that in 2017, I would meet a man who loves me, that I was going to work, that I would be alive and that I would be better, I would not have believed you!" | englishlongbow | |
21/1/2018 11:41 | 'You'd never have known I was sick' :) | lodgeview | |
21/1/2018 10:17 | Thanks, i also have googled Barbi Manchester and have not found out much. Can anyone tell me if she actually took the IMM drug and that it has een shown to work, with her recovery. | happyman7 | |
21/1/2018 01:04 | I think one poster stated that barbie did not get to use lupuzor under right to try after the trial, but has had gene therapy since. | l0ngterm | |
21/1/2018 01:02 | Barbie was on one of the trials,link below. others have posted more information, follow up info etc.http://www.mtair | l0ngterm | |
21/1/2018 00:19 | as a matter of interest , does anyone know what is Barbi Manchester's, a lupus sufferer, connection with IMM, had she been taking the drug, although not oficially (yet) from the regulator. Are there any other Lupus patients who have been taking under the auspices of IMM, not on the official radar of the formal testing. | happyman7 | |
20/1/2018 22:10 | 3 interviews - (proactive investors) IMM starts at 27:01 | metis20 | |
20/1/2018 21:49 | Remarkomsoc , the 8th and 9th were the best | lukead | |
20/1/2018 21:33 | Brad, I have watched both interviews and my honest opinion is this is going to be a success. I have over £20k invested here so I am looking at at least a 40 bagger from here which will almost make me a millionaire. | lodgeview | |
20/1/2018 21:23 | lodgeview, watch the interview and gauge for yourself would be my reply | brad44 | |
20/1/2018 21:22 | NY Boy, just use the filter button, at this stage of the process, its bound to be volatile, and every clown on the planet will be here before the end of Q1, if we think we know what will happen does... | brad44 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions